QIAGEN Releases QIAstat-Dx Test Kit as the First Syndromic Test to Detect COVID-19 Under New FDA Policy

 QIAGEN Releases QIAstat-Dx Test Kit as the First Syndromic Test to Detect COVID-19 Under New FDA Policy

QIAGEN Releases QIAstat-Dx Test Kit as the First Syndromic Test to Detect COVID-19 Under New FDA Policy

Shots:

  • QIAGEN has started the shipment of its QIAstat-Dx Respiratory SARS-CoV-2 Panel test to the US for diagnosing the patients infected with COVID-19 under a new FDA’s policy, announced on Mar 16, 2020
  • The QIAstat-Dx test is a multiplexed nucleic acid test that assesses samples such as nasopharyngeal swabs obtained from individuals suspected of the respiratory tract and can differentiate the SARS-CoV-2 from 20 other respiratory infections
  • The kit requires < 1min. for preparing the sample and delivers results in ~1hr. The company is expected to submit EUA to the US FDA this week

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: QIAGEN

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post